Resultados de la búsqueda 311-320 of 13549 for Dr. Benjamin Brinkmann

1. Cirugía - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. The purpose of this study is to evaluate thymoma recurrence rates in patients who underwent thymectomy. 3D Ultrasound Imaging for Breast Cancer ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) ...

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping ...

4. Neurología - Ensayos clínicos - Mayo Clinic

   ... Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, ...

7. Neurología - Ensayos clínicos - Mayo Clinic

   ... Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   We hypothesize that targeting melanoma with a PD-1 (MC9324) CAR TIL therapy would capitalize on the tumor homing machinery of the TIL to drive ... Dr. Joseph ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...